XU, GUOXIONG, MD, PhD
Professor of Oncology, Scientist, Director
Center Laboratory, Jinshan Hospital, Fudan University

LEGAL STATUS: Canadian Citizen

LANGUAGES: English (fluent), Chinese (native), French (basic)

EDUCATION:

PhD, Biology, 2007	York University, Toronto, Canada
Master, Medical and Pharmaceutical Research, 1994	Free University of Brussels, Belgium
Bachelor, Medicine, 1983	Shanghai Second Medical University, China

PROFESSIONAL EXPERIENCE:

Date	Position	Department/Field	Institution
12.2011- present	Scientist/Director	Center Laboratory	Jinshan Hospital, Fudan University, Shanghai, China
08.2009-02.2012	Scientist	Diabetes Group	Institute Pasteur Korean, Seoul, Korea
09.2007-08.2009	Research Fellow	Molecular Structure and Function Program	Hospital for Sick Children, University of Toronto, Canada
06.2002-08.2007	Research Associate	Biology	York University, Toronto, Canada
05.2000–05.2002	Research Associate	Anatomy and Cell Biology	University of Western Ontario, Canada
08.1998-05.2000	Research Associate	Liver Center Laboratory	Duke University Medical Center, USA
11.1995-08.1998	Research Associate	Pathology	University of Geneva, Geneva, Switzerland
05.1991-11.1995	Research Associate	Cell Biology and Histology	Free University of Brussels (VUB), Brussels, Belgium
02.1991-04.1991	Visiting Doctor	Gastroenterology	Erasme Hospital, Universit é Libre de Bruxelles, Belgium
07.1989-01.1991	Attending Physician	Internal Medicine	Jinshan Hospital, Shanghai Medical University, Shanghai, China
01.1988-03.1989	Visiting Doctor	Gastroenterology	Huashan Hospital, Shanghai Medical University, Shanghai, China
07.1988-07.1989	Chief Resident	Internal Medicine	Jinshan Hospital, Shanghai Medical University, Shanghai, China
08.1983-07.1988	Resident	Internal Medicine	Jinshan Hospital, Shanghai 1st Medical College, Shanghai, China

TEACHING EXPERIENCE:

2013-present *Molecular Biology of Cancer*, undergraduate course	Fudan University
2012 *Experimental Methodology in Biomedical Research,* graduate course	Jinshan Hospital
2007 *Advanced Biochemistry & Molecular Genetics*, undergraduate course	York University
2006 *Animal Physiology,* the 3rd year undergraduate course in Biology	York University

2005-06 *Biological Science,* the 1st year undergraduate course in Biology York University
2005 Genetics, the 2nd year undergraduate course in Biology York University
2004-06 *The Biology of Sex*, the 1st year undergraduate course in Natural Science York University
2004 *Cell Biology & Biochemistry*, the 2nd year undergraduate course in Biology York University
2003 *Histology,* the 4th year undergraduate course in Biology York University

SUPERVISOR/MENTORSHIP

Postdoctoral fellow: Xiaoling Tian (2015-2017)

Ph.D. student: Weimin Ren (2016-2019), Lingyun Zhang (2013-2018 transfer from Master)

Master student: Fanchen Wang (2017-2020), Fangran Liu (2017-2020), Jinguo Zhang (2016-2019), Qunbo Lin (2015-2018), Daibing Zhou (2014-2017), Wenwen Sun (2013-2016), Xingxing Wang (2011-2014)

Exchange Student by International Federation of Medical Students' Association (IFMSA): Stefano Paolini (Italy 2017), Roman Tulupov & Anna Saveleva (Russia 2017), Barbara Simone (Italy 2016), Miina Koskela (Finland 2016), Klaudia Malec (Poland 2016), Maria Teresa Pina Vaz Gonçalves Rodrigues (Portugal 2015), Ewa Chmielewska (Poland 2015)

HONORS AND AWARDS:

Award for the outstanding service, Jinshan Hospital of Fudan University 2017
Award of Outstanding Talent in the 9th period, Commission of Health and Family Planning of Jinshan District 2016-2018
Award for the outstanding service, Jinshan Hospital of Fudan University 2016
Excellent teacher, Jinshan Hospital of Fudan University 2015-2016
Award of Outstanding Talent in the 8th period, Commission of Health and Family Planning of Jinshan District 2014-2016
Award for the extraordinary service, Jinshan Hospital of Fudan University 2014
First Prize for the presentation of scientific paper, Jinshan Hospital of Fudan University 2014
Excellent teacher, Jinshan Hospital of Fudan University 2013-2014
Award for an outstanding achievement, The 18th World Congress on Advances in Oncology and 16th International Symposium on Molecular Medicine (Greece) 2013
Award for an Outstanding Leading Talent in the Reserve Team, Shanghai Jinshan District 3013
The 5th Advanced Science and Technology Award, Jinshan Hospital of Fudan University 2012
Research Fellowship Award, Heart and Stroke Foundation of Canada (Canada) 2007-2009
The 4th CCOCR Travel Award, Canadian Conference on Ovarian Cancer Research (Canada) 2008
Women's Health Scholars Award, Ontario Council on Graduate Studies/Ontario Women's Health Council (Canada) 2005-2007
Professional Development Fund Award, York University (Canada) 2004-2007
The 3rd NCOCR Travel Award, National Conference on Ovarian Cancer Research (Canada) 2006
Graduate Development Fund Award, York University (Canada) 2004-2006
First Prize for the poster presentation, The 32nd Annual Southern Ontario Reproductive Biology (SORB) Workshop (Canada) 2004
VUB-Scholarship, Free University of Brussels (VUB) (Belgium) 1995

PROFESSIONAL MEMBERSHIPS:

Member of Tumor Biomarker Committee of Chinese Anti-Cancer Association 2017- present
Permanent Member of Chinese Society for Cell Biology 2017- present
Member of Shanghai Medical Association 2013- present
Associate Member of Canadian Society of Biochemistry, Molecular & Cellular Biology 2004-present

Active Member of American Association for Cancer Research 2001-present
Associate Member of the Endocrine Society 2007 - 2008
Associate Member of Society for the Study of Reproduction 2005 - 2007

EDITORIAL BOARD

Member of the Editorial Board of Cancer Translational Medicine 2017- present
Associate Editor of Journal of Cancer Biology & Research 2017- present
Member of the Editorial Board of Current Cancer Therapy Reviews 2017- present
Member of the Editorial Board of Cancer Cell Research 2017- present
Member of the Editorial Board of Pathology and Laboratory Medicine 2017- present
Member of the Editorial Board of Journal of Solid Tumors 2017- present
Member of the Editorial Board of Journal of Cancer Research and Therapeutic Oncology 2016- present
Member of the Editorial Board of Oncology Communications 2016- present
Member of the Editorial Board of International Journal of Cancer Research & Therapy 2016- present
Member of the Editorial Board of China Medical Herald 2015- present
Vice Chief Editor of Medical Cell Biology 2015-2017
Member of the Editorial Board of American Journal of Biomedical Research 2014- present
Member of the Editorial Board of HSOA Journal of Neurocardiovascular Diseases 2014-2015
Member of the Editorial Board of Oncology Reports 2013- present

REVIEWING MEMBERSHIPS

Member of Grant Review, China Postdoctoral Science Foundation 2017-present
Communication Reviewer for Outstanding Thesis, China Academic Degrees & Graduate Education, Ministry of Education, China 2015-present
Reviewer for Outstanding Thesis, Shanghai Academic Degrees & Graduate Education, Shanghai Committee of Academic Degrees 2015-present
Communication Member of Grant Review, Committee of National Natural Science Foundation of China 2013-present
Penal member of Grant Review, Committee of Scientific Fund in Committee of Science and Technology of Jinshan District 2012-present
Penal member of Grant Review, Committee of Scientific Fund in Jinshan District Health Bureau 2012-present

PUBLIC SERVICE

Judge of poster presentation at the 7th International Conference and Expo on Molecular & Cancer Biomarkers, Berlin, Germany September 16, 2016
Vice President, Shanghai Overseas Returned Scholars Association Jinshan Branch 2015-present
Vice Chairman, the Ethics Committee of Jinshan Hospital, Fudan University, China 2012-present
Member of the PDF Seminar Committee, Research Institute, The Hospital for Sick Children, University of Toronto, Canada 2007 - 2009
Judge of poster presentation at the 1st Annual Ontario Medical Student Research Day/the 23rd Annual University of Toronto Medical Student Research Day, Toronto, Canada April 25-26, 2009

RESEARCH SUPPORT

Science and Technology Commission of Shanghai Municipality (ID# 17ZR1404100): Mechanistic study on PNPO regulating the reversal of paclitaxel resistance in ovarian cancer. Support period: 01/05/2017 - 30/04/2017. Role: PI.

Shanghai Municipal Commission of Health and Family Planning (ID# 201640287): Role and regulating mechanism of pyridoxine 5'-phosphate oxidase in breast invasive ductal carcinoma. Support period: 01/01/2017 - 31/12/2019. Role: PI.

National Natural Science Foundation of China (ID# 81272880): Role and mechanism of TGF-β signaling pathway in regulating potential biomarkers for ovarian cancer. Support period: 01/01/2013 - 31/12/2016. Role: PI.

Shanghai Municipal Health Bureau (ID# 20124186): Effect of potential biomarkers in ovarian cancer. Support period: 01/01/2013 - 31/12/2015. Role: PI.

Science and Technology Commission of Shanghai Municipality (ID# 124119b1300): Explore clinical value of potential biomarkers for early ovarian cancer and its mechanism. Support period: 01/10/2012 - 31/09/2015. Role: PI.

Jinshan Hospital of Fudan University (ID# 2012-02): Title of Proposal: Regulation of potential biomarkers of ovarian cancer by TGF-β signaling pathway. Support period: 01/01/2012 - 31/12/2014. Role: PI.

Shanghai Municipal Health Bureau (ID# 20124140): Studying the effect of CpG ODN on the radiation-induced lung injury. Support period: 01/01/2013 - 31/12/2015. Role: Co-PI.

National Natural Science Foundation of China (ID# 81471628): Quantitative biomarkers of MR functional imaging in the evaluation of biological traits of borderline epithelial ovarian tumors. Support period: 01/01/2015 - 31/12/2018. Role: Co-PI.

Ovarian Cancer Canada: Title of Proposal: Proteins differentially expressed in OSE of BRCA1 carriers as potential biomarkers of ovarian cancer. Support period: 01/07/2008 - 30/06/2009. Role: Co-PI.

PATENT (Patent of Invention, Approved)

1. **Xu G**, Zhang L. shRNA structure acting on PNPO genes and application of shRNA structure (China # ZL201510273999.1).
2. **Xu G**, Zhang L. Method for establishing paclitaxel (PTX)-resistant ovarian cancer cell model (China, # ZL201410708515.7).
3. **Xu G**, Zhu YY, Zhang L. Triple marker used for diagnosing breast cancer and application thereof (China, # ZL201510394950.1).
4. Chen Y, Shi X, **Xu G**, Li B, Chen B. Application of TNF (tumor necrosis factor)-alpha receptor-antibody fusion protein in preparation of medicament (China, # CN201210342183.6).

PATENT (Patent of Invention, Submitted)

1. **Xu G**, Ren W. A new method for the diagnosis of invasive ductal carcinoma of the breast. China (Application number 201710738785.6). Submitted on August 25, 2017.
2. Xu G, Zhang L. The use of FLOT1 as a biomarker in ovarian cancer. China (Application number 201710536540.5). Submitted on July 04, 2017.
3. **Xu G**, Shi Jimin, Zhang L. The application of RPL10 inhibitor in preparing medicine for the treatment of ovarian cancer. China (Application number 201710427474.8). Submitted on June 08, 2017.
4. **Xu G**, Zhang J, Zhang L. A carboplatin resistant ovarian cancer cell line and its application. China (Application number 201710290708.9). Submitted on April 28, 2017.
5. Xu G, Zhang L. Applications of phosphopyridoxal in preparing medicines for treating ovarian cancer. China (Application number 201611096574.9). Submitted on December 01, 2016.
6. **Xu G,** Zhou D. Application of CMPK (cytidine monophosphate kinase) inhibitor in preparing ovarian cancer treatment drugs. China (Application number 201611055534.X). Submitted on November 25, 2016.

7. **Xu G,** Tian X, Guan W. Application of STAT1 serving as ovarian cancer treatment target point. China (Application number 201610960314.5). Submitted on October 28, 2016.
8. **Xu G,** Guan W, Tian X. STAT1 (signal transducer and activator of transcription 1) recombinant expression plasmids and preparation. China (Application number 201610099784.7). Submitted on February 24, 2016.
9. **Xu G**, Zhang L. Reduction of pyridoxine 5'-phosphate oxidase (PNPO) for treating ovarian cancer. China (Application number 201510274010.9). Submitted on May 27, 2015.

PATENT (Patent of Utility Model, Submitted)

1. Ren W, Xiaobo Yang, **Xu G**. A split type trash can used in the laboratory. China (Application number 201710738785.6). Submitted on August 25, 2017.

BOOK PUBLICATIONS:

1. Liu J, **Xu G**, Liu X. Medical Cell Biology. People's Medical Publishing House 2017.

ARTICLE PUBLICATIONS:

1. Zhang J, Zhang L, Lin Q, Ren W, **Xu G**. Prognostic value of endoglin-assessed microvessel density in cancer patients: a systematic review and meta-analysis. Oncotarget. 2017 Dec; Epub.
2. Zhang L, Zhou D, Guan W, Ren W, Sun W, Shi J, Lin Q, Zhang J, Qiao T, Ye Y, Wu Y, Zhang Y, Zuo X, Connor KL, **Xu G**. Pyridoxine 5'-phosphate oxidase is a novel therapeutic target and regulated by the TGF-β signalling pathway in epithelial ovarian cancer. Cell Death Dis. 2017 Dec 13; 8(12):3214.
3. Zhang J, Zhou D, Zhang L, Lin Q, Ren W, Zhang J, Nadeem L, **Xu G**. Dual Effects of N,N-dimethylformamide on Cell Proliferation and Apoptosis in Breast Cancer. Dose Response. 2017 Dec 5; 15(4):1559325817744450.
4. Ding L, Zeng Q, Wu J, Li D, Wang H, Lu W, Jiang Z, **Xu G**. Caveolin-1 regulates oxidative stress-induced senescence in nucleus pulposus cells primarily via the p53/p21 signaling pathway in vitro. Mol Med Rep. 2017 Dec; 16(6):9521-9527.
5. Zhou D, Zhang L, Lin Q, Ren W, **Xu G**. Data on the association of CMPK1 with clinicopathological features and biological effect in human epithelial ovarian cancer. Data Brief. 2017 Aug; 13: 77-84.
6. Zhang J, **Xu G**. Advances in the clinical application of liquid biopsy for circulating tumor cells and circulating tumor DNA in hepatocellular carcinoma. Chinese Hepatology (Chinese). 2017, 22(5):467-469.
7. Zhou D, Zhang L, Sun W, Guan W, Lin Q, Ren W, Zhang J, **Xu G**. Cytidine monophosphate kinase is inhibited by the TGF-β signalling pathway through the upregulation of miR-130b-3p in human epithelial ovarian cancer**.** Cell Signal. 2017 Apr 14; 35:197-207.
8. Wang Z, Jia G, Li Y, Liu J, Luo J, Zhang J, **Xu G**, Chen G. Clinicopathological signature of p21-activated kinase 1 in prostate cancer and its regulation of proliferation and autophagy via the mTOR signaling pathway. Oncotarget. 2017 Apr 4; 8(14):22563-22580.
9. Chen X, Zhang Q, Luo Y, Gao C, Zhuang X, **Xu G**, Qiao T. High-dose irradiation in combination with toll-like receptor 9 agonist cpg oligodeoxynucleotide 7909 downregulates PD-l1 expression via the NF-κB signaling pathway in non-small cell lung cancer cells. Onco Targets Ther. 2016 Oct 21; 9:6511-6518.
10. Zhang J, Shao Y, He D, Zhang L, **Xu G**, Shen J. Evidence that bone marrow-derived mesenchymal stem cells reduce epithelial permeability following phosgene-induced acute lung injury via activation of wnt3a protein-induced canonical wnt/β-catenin signaling. Inhal Toxicol. 2016 Oct; 28(12):572-579.

11. Zhuang X, Qiao T, **Xu G**, Yuan S, Zhang Q, Chen X. Combination of nadroparin with radiotherapy results in powerful synergistic antitumor effects in lung adenocarcinoma A549 cells. Oncol Rep. 2016 Oct; 36(4):2200-2206.
12. Li X, **Xu G**, Qiao T, Yuan S, Zhuang X, Zhang J, Sun HB. Effects of CpG Oligodeoxynucleotide 1826 on transforming growth factor-beta 1 and radiation-induced pulmonary fibrosis in mice. J Inflamm (Lond). 2016 May 17; 13:16.
13. Zhang L, Nadeem L, Connor K, **Xu G**. Mechanisms and therapeutic targets of microRNA-associated chemoresistance in epithelial ovarian cancer. Curr Cancer Drug Targets. 2016; 16(5):429-441.
14. Sun W, Gui L, Zuo X, Zhang L, Zhou D, Duan X, Ren W, **Xu G**. Human epithelial-type ovarian tumour marker beta-2-microglobulin is regulated by the TGF-β signaling pathway. J Transl Med. 2016 Mar 16;14(1):75.
15. Li X, **Xu G**, Qiao T, Yuan S, Zhuang X. Effects of CpG oligodeoxynucleotide 1826 on acute radiation-induced lung injury in mice. Biol Res. 2016 Feb 3; 49:8.
16. Ding L, Wu J, Li D, Wang H, Zhu B, Lu W, **Xu G**. Effects of CCN3 on rat cartilage endplate chondrocytes cultured under serum deprivation in vitro. Mol Med Rep. 2016 Mar; 13(3):2017-2022.
17. Zhu Y, Guo M, Zhang L, Xu T, Wang L, **Xu G**. Biomarker triplet NAMPT/VEGF/HER2 as a de novo detection panel for the diagnosis and prognosis of human breast cancer. Oncol Rep. 2016 Jan; 35(1):454-462.
18. Zhou D, Zhang L, **Xu G**. Advances in the Mechanisms of piRNA/PIWI in Hepatocellular Carcinoma. Chinese Hepatology (Chinese) 2016, 21(8):696-699.
19. Zhou D, **Xu G**. Application progress of molecular probes in magnetic resonance imaging targeting detection for the tumor. China Medical Herald (Chinese) 2016, 13(18):46-48.
20. Tian X, **Xu G**. Clinical value of lncRNA MALAT1 as a prognostic marker in human cancer: systematic review and meta-analysis. BMJ Open 2015 Sep 30; 5(9):e008653.
21. Han D, Jin J, Fang H, **Xu G**. Long-term action of propofol on cognitive function and hippocampal neuroapoptosis in neonatal rats. Int J Clin Exp Med. 2015 Jul 15; 8(7):10696-10704.
22. Li Y, **Xu G**, Huang K, Wang J, Zhang J, Liu J, Wang Z, Chen G. Alteration of ASIC I expression in clear cell renal cell carcinoma. Onco Targets Ther. 2015 Aug 14; 8:2121-2127.
23. Lv X, Zhang L, Zhu Y, Said HM, Shi J, **Xu G**. Regulative effect of Nampt on tumor progression and cell viability in human colorectal cancer. J Cancer. 2015 Jul 16; 6(9):849-858.
24. Zhuang X, Qiao T, **Xu G**, Chen X, Yuan S, Zhang Q, Xing N, Chen W. Establishment of a radioresistant cell strain of Lewis lung cancer cells. Chin J Radiol Med Prot 2015, 35(11):805-808.
25. Zhang L, **Xu G**. Effects of vitamin metabolism on hepatocellular carcinoma. Chinese Hepatology (Chinese) 2015, 20(8):638-641.
26. Xing N, Qiao T, Zhuang X, Yuan S, Zhang Q, **Xu G**. CpG oligodeoxyribonucleotide 7909 enhances radiosensitivity via downregulating Oct-4 expression in radioresistant lung cancer cells. Onco Targets Ther. 2015 Jun 12; 8:1443-1449.
27. Chen J, Shao Y, **Xu G**, Lim C, Li J, Xu D, Shen J. Bone marrow-derived mesenchymal stem cells attenuate phosgene-induced acute lung injury in rats. Inhal Toxicol. 2015; 27(5):254-261.
28. Zhang L, Fan X, Zhong Z, **Xu G**, Shen J. Association of plasma diamine oxidase and intestinal fatty acid-binding protein with severity of disease in patient with heat stroke. Am J Emergency Med 2015 Jul; 33(7):867-871.
29. Huang K, Chen G, Luo J, Zhang Y, **Xu G**. Clinicopathological and cellular signature of PAK1 in human bladder cancer. Tumor Biology. 2015 Apr; 36(4):2359-2368.
30. Chen Y, Xiao X, Wang C, Jiang H, Hong Z, **Xu G**. Beneficial effect of tetrandrine on refractory epilepsy via suppressing P-glycoprotein. Int J Neurosci. 2015; 125(9):703-710.

31. Li D, Zhu B, Ding L, Lu W, **Xu G**, Wu J. Role of the mitochondrial pathway in serum deprivation-induced apoptosis of rat endplate cells. Biochem Biophys Res Commun. 2014 Sep 26; 452(3):354-360.
32. Ding L, Wu JP, **Xu G**, Zhu B, Zeng QM, Li DF, Lu W. Lentiviral-mediated RNAi targeting caspase-3 inhibits apoptosis induced by serum deprivation in rat endplate chondrocytes in vitro. Braz J Med Biol Res. 2014 Jun; 47(6):445-451.
33. Wang X, Gui L, Zhang Y, Zhang J, Shi J, **Xu G**. Cystatin B is a progression marker of human epithelial ovarian tumor mediated by the TGF-β signaling pathway. Int J Oncol. 2014 Apr; 44(4):1099-1106.
34. Peng F, Gong H, Nadeem L, Zhang L, **Xu G**. MicroRNA associated with generation, development, and maintenance of atrial fibrillation. J Cardiol Neurocardiovasc Dis. 2014; 1:003.
35. **Xu G**, Barrios-Rodiles M, Jerkic M, Turinsky AL, Nadon R, Vera S, Voulgaraki D, Wrana JL, Toporsian M, Letarte M. Novel protein interactions with endoglin and activin receptor-like kinase 1: potential role in vascular networks. Mol Cell Proteomics. 2014 Feb; 13(2):489-502.
36. Liu Z, Yang Y, Zhang Y, Ye X, Wang L, **Xu G**. Stomatin-like protein 2 is associated with the clinicopathological features of human papillary thyroid cancer and is regulated by TGF-β in thyroid cancer cells. Oncol Rep. 2014 Jan; 31(1):153-160.
37. He DK, Shao YR, Zhang L, Shen J, Zhong ZY, Wang J, **Xu G**. Adenovirus-delivered angiopoietin-1 suppresses NF-kB and p38 MAPK and attenuates inflammatory responses in phosgene-induced acute lung injury. Inhal Toxicol. 2014; 26(3):185-192.
38. Shen J, Gan Z, Zhao J, Zhang L, **Xu G**. Ulinastatin reduces pathogenesis of phosgene-induced acute lung injury in rats. Toxicol Ind Health. 2014 Oct; 30(9):785-793.
39. Gregory AL, **Xu G**, Sotov V, Letarte M. Review: The enigmatic role of endoglin in the placenta. Placenta. 2014; 35S:S93-S99.
40. Chen C, Liu J, **Xu G**. Overexpression of PIWI proteins in human stage III epithelial ovarian cancer with lymph node metastasis. Cancer Biomarkers. 2013; 13(5):315-321.
41. Shi X, Chen Y, Nadeem L, **Xu G**. Beneficial effect of TNF-α inhibition on diabetic peripheral neuropathy. J Neuroinflammation. 2013 Jun 4; 10:69.
42. Yan L, **Xu G**, Qiao T, Chen W, Yuan S, Li X. CpG-ODN 7909 increases radiation sensitivity of radiation-resistant human lung adenocarcinoma cell line by overexpression of toll-like receptor 9. Cancer Biother Radiopharm. 2013 Sep; 28(7):559-564.
43. Wei J, Feng L, Li Z, **Xu G**, Fan X. MicroRNA-21 activates hepatic stellate cells via PTEN/Akt signaling. Biomed Pharmacother. 2013 Jun; 67(5):387-392.
44. Shen J, Wang J, Shao YR, He DK, Zhang L, Nadeem L, **Xu G**. Adenovirus-delivered angiopoietin-1 treatment for phosgene-induced acute lung injury. Inhal Toxicol. 2013 Apr; 25(5):272-279.
45. Yu H, **Xu G**, Fan X. The effect of ghrelin on cell proliferation in small intestinal IEC-6 cells. Biomed Pharmacother. 2013 Apr; 67(3):235-239.
46. Chen YH, Wang CC, Xiao X, Wei L, **Xu G**. Multidrug resistance-associated protein 1 decreases the concentrations of antiepileptic drugs in cortical extracellular fluid in amygdale kindling rats. Acta Pharmacol Sin. 2013 Apr; 34(4):473479.
47. Chen Y, Xiao X, Wang Z, Wang C, Wei L, **Xu G**. The expression of pannexin-1 in the cortex of rats with epilepsy. J Neurosci Ment Health (Chinese) 2012, 12 (5):457-459.
48. Eguchi M, **Xu G**, Li RK, Sweeney G. Diabetes influences cardiac extracellular matrix remodeling after myocardial infarction and subsequent development of cardiac dysfunction. J Cell Mol Med. 2012, 16(12):2925-2934.

49. Chen Y, Zhao Y, Wang C, Xiao X, Zhou X, **Xu G**. Inhibition of p38 MAPK diminishes doxorubicin-induced drug resistance associated with P-glycoprotein in human leukemia K562 cells. Med Sci Monit. 2012 Oct; 18(10):BR383-388.
50. De Silva T, Ye G, Liang Y-Y, Fu G, **Xu G**, Peng C. Nodal Promotes glioblastoma cell growth. Front Endocrinol 2012, 3:59.
51. **Xu G**, Ahn J, Chang S, Eguchi M, Ogier A, Han S, Park Y, Shim C, Jang Y, Yang B, Xu A, Wang Y, Sweeney G. Lipocalin-2 induces cardiomyocyte apoptosis by increasing intracellular iron accumulation. J Biol Chem 2012, 287(7):4808-4817.
52. Zeng F, **Xu G**, Zhou T, Yang C, Wang X, Peng C, Zhou H. Reduced expression of activin receptor-like kinase 7 in breast cancer is associated with tumor progression. Med Oncol 2012, 29(4):2519-2526.
53. Zhong Y, **Xu G**, Ye G, Lee D, Modica-Amore J, Peng C. Nodal and activin receptor-like kinase 7 induce apoptosis in human breast cancer cell lines: Role of caspase 3. Int J Physiol Pathophysiol Pharmacol 2009, 1(1):83-96.
54. **Xu G**, Bernaudo S, Fu G, Lee DY, Yang BB, Peng C. Cyclin G2 is degraded through the ubiquitin-proteasome pathway and mediates the antiproliferative effect of activin receptor-like kinase 7. Mol Biol Cell 2008, 19(11):4968-4979.
55. **Xu G**, Zhou H, Wang Q, Auersperg N, Peng C. Activin receptor-like kinase 7 induces apoptosis through up-regulation of Bax and down-regulation of Xiap in normal and malignant ovarian epithelial cell lines. Mol Cancer Res 2006, 4(4):235-246 (**Selected for cover feature**).
56. Zhang N, Kumar M, **Xu G**, Ju W, Yoon T, Xu E, Huang X, Gaisano H, Peng C, Wang Q. Activin receptor-like kinase 7 induces apoptosis of pancreatic beta cells and beta cell lines. Diabetologia 2006, 49(3):506-518.
57. **Xu G**, Zhong Y, Munir S, Yang BB, Tsang BK, Peng C. Nodal induces apoptosis and inhibits proliferation in human epithelial ovarian cancer cells via activin receptor-like kinase 7. J Clin Endocrinol Metab 2004, 89(11):5523-5534.
58. Munir S, **Xu G**, Wu Y, Yang B, Lala PK, Peng C. Nodal and ALK7 inhibit proliferation and induce apoptosis in human trophoblast cells. J Biol Chem 2004, 279(30):31277-31286.
59. Timoshenko AV, **Xu G**, Chakrabarti S, Lala PK, Chakraborty C. Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells. Exp Cell Res 2003, 289(2):265-274.
60. **Xu G**, Chakraborty C, Lala PK. Reconstitution of Smad3 restores TGF-β response of tissue inhibitor of metalloprotease-1 upregulation in human choriocarcinoma cells. Biochem Biophys Res Commun 2003, 300(2):383-390.
61. **Xu G**, Guimond MJ, Chakraborty C, Lala PK. Control of proliferation, migration and invasiveness of the human extravillous trophoblast by decorin, a decidual product. Biol Reprod 2002, 67(2):681-689.
62. **Xu G**, Chakraborty C, Lala PK. Restoration of TGF-β regulation of plasminogen activator inhibitor-1 in Smad3-restituted human choriocarcinoma cells. Biochem Biophys Res Commun 2002, 294(5):1079-1086.
63. Lala PK, Lee BP, **Xu G**, Chakraborty C. Human placental trophoblast as an in vitro model for tumor progression. Can J Physiol Pharmacol 2002, 80(2):142-149.
64. **Xu G**, Chakraborty C, Lala PK. Expression of TGF-β signaling genes in the normal, premalignant and malignant human trophoblast: loss of smad3 in choriocarcinoma cells. Biochem Biophys Res Commun 2001, 287(1):47-55.
65. **Xu G**, Bochaton-Piallat ML, Andreutti D, Low RB, Gabbiani G, Neuville P. Regulation of α-smooth muscle actin and CRBP-1 expression by retinoic acid and TGF-β in cultured fibroblasts. J Cell Physiol 2001, 187(3):315-325.

66. De Bleser PJ, **Xu G**, Rombouts K, Rogiers V, Geerts A. Glutathione levels discriminate between oxidative stress and transforming growth factor-β signaling in activated rat hepatic stellate cells. J Biol Chem 1999, 274(48):33881-33887.
67. Desmoulière A, **Xu G**, Costa AM, Yousef IM, Gabbiani G, Tuchweber B. Effect of pentoxifylline on early proliferation and phenotypic modulation of fibrogenic cells in two rat models of liver fibrosis and on cultured hepatic stellate cells. J Hepatol 1999, 30(4):621-631.
68. **Xu G**, Redard M, Gabbiani G, Neuville P. Cellular retinol binding protein-1 is transiently expressed in granulation tissue fibroblasts and differentially expressed in fibroblasts cultured from different organs. Am J Pathol 1997, 151(6):1741-1749.
69. De Bleser PJ, Niki T, **Xu G**, Rogiers V, Geerts A. Localization and cellular sources of activins in normal and fibrotic rat liver. Hepatology 1997, 26(4):905-912.
70. **Xu G**, Niki T, Virtanen I, Rogiers V, De Bleser P, Geerts A. Gene expression and synthesis of fibronectin isoforms in rat hepatic stellate cells. Comparison with liver parenchymal cells and skin fibroblasts. J Pathol 1997, 183(1):90-98.
71. Niki T, De Bleser PJ, **Xu G**, Van Den Berg K, Wisse E, Geerts A. Comparison of glial fibrillary acidic protein and desmin staining in normal and CCl_4-induced fibrotic rat livers. Hepatology 1996, 23(6):1538-1545.
72. De Bleser PJ, Scott CD, Niki T, **Xu G**, Wisse E, Geerts A. Insulin-like growth factor-II/mannose 6-phosphate-receptor expression in liver and serum during acute CCl_4-intoxication of the rat. Hepatology 1996, 23(6):1530-1537.